Urology Austin, PLLC Trials

Urology Austin, PLLC	Welcome, Profile Billing Logout

45 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Hafron, Jason

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting

325

Cretostimogene Grenadenorepvec, CG0070

CG Oncology, Inc.

High-Risk Non-Muscle-Invasive Bladder Cancer

03/27

12/27

NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting

N/A

650

ADXBLADDER

Arquer Diagnostics Ltd

Bladder Cancer

01/23

04/23

Preston, Mark

NCT03216525: Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Recruiting

136

Alvimopan, Entereg, Placebo

Brigham and Women's Hospital, Merck Sharp & Dohme LLC

Bladder Cancer

12/23

06/24

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

350

Europe, Canada, US, RoW

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/26

11/28

Rendon, Ricardo

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting

1100

Europe, Canada, US, RoW

Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy

University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium

Prostate Cancer

01/28

07/28

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting

125

Canada, US

Ruvidar® (TLD-1433) Bladder infusion and PDT

Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

06/25

12/25

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

350

Europe, Canada, US, RoW

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/26

11/28

Kates, Max

NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting

112

Europe, US

ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)

Fidia Farmaceutici s.p.a.

Bladder Carcinoma in Situ (CIS)

11/25

11/27

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting

Europe, US

UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine

UroGen Pharma Ltd.

Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent

12/25

BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting

N/A

4400

Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system

Photocure, Catalyst Pharmaceutical Research

Bladder Cancer

12/28

Dickstein, Rian

BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting

190

Japan, US, RoW

Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer

12/27

12/29

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

350

Europe, Canada, US, RoW

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/26

11/28

PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting

ZH9

Prokarium Ltd

NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer

06/25

07/27

CREDIBLE, NCT06394869: Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Recruiting

N/A

1000

Cxbladder Triage Plus

Pacific Edge Limited

Hematuria - Cause Not Known

01/27

03/27

uTRACT, NCT05874921: Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Recruiting

N/A

400

Jelmyto (mitomycin) for pyelocalyceal solution, Jelmyto, UGN-101

UroGen Pharma Ltd.

Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis

04/26

01/28

Mazzarella, Brian

ARID II, NCT06873581: Pivotal Study of Voro Urologic Scaffold

Recruiting

266

Voro Urologic Scaffold

Levee Medical, Inc.

Radical Prostatectomy, Stress Urinary Incontinence (SUI)

02/27

02/28

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting

325

Cretostimogene Grenadenorepvec, CG0070

CG Oncology, Inc.

High-Risk Non-Muscle-Invasive Bladder Cancer

03/27

12/27

BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting

N/A

279

Zenflow Spring System, Sham Procedure, Foley Catheter

Zenflow, Inc.

BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)

06/24

06/26

NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Terminated

N/A

NanoTherm Ablation

MagForce USA

Prostate Cancer

07/23

NCT05186740: ProVee Urethral Expander System IDE Study (ProVIDE)

Active, not recruiting

N/A

221

Europe, Canada, US

ProVee Urethral Expander System, ProVee Expander, ProVee, Urethral Access Sheath

ProVerum Medical

Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms

03/24

12/28

NCT06236802: ProVIDE II Bridging Study

Active, not recruiting

N/A

Europe, US

ProVee device, ProVee Expander, ProVee

ProVerum Medical

BPH With Symptomatic Lower Urinary Tract Symptoms

09/24

06/29

NCT06496256: Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

Recruiting

N/A

US, RoW

Barrigel, Transrectal Ultrasound

Palette Life Sciences, Inc., Teleflex

Prostate Cancer

12/27

CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm

Active, not recruiting

N/A

120

Europe, US

UroLift, Rezum

NeoTract, Inc.

Benign Prostatic Hyperplasia

05/25

12/25

WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting

N/A

280

Europe, Canada, US, RoW

Aquablation Therapy, Radical Prostatectomy

PROCEPT BioRobotics

Localized Prostate Cancer

07/27

01/37

VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting

N/A

400

Vanquish System

Francis Medical Inc.

Prostate Cancer

04/27

04/29

Santoyo, Jose

NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting

1/2

STM-416

SURGE Therapeutics

Non-muscle-invasive Bladder Cancer

12/25

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

350

Europe, Canada, US, RoW

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/26

11/28

Penshorn, Jennifer

NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Terminated

N/A

NanoTherm Ablation

MagForce USA

Prostate Cancer

07/23

NCT06496256: Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

Recruiting

N/A

US, RoW

Barrigel, Transrectal Ultrasound

Palette Life Sciences, Inc., Teleflex

Prostate Cancer

12/27

NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Recruiting

N/A

125

US, RoW

Robotic Waterjet Treatment, Aquablation therapy

PROCEPT BioRobotics

Benign Prostatic Hyperplasia, Localized Prostate Cancer

08/25

05/26

VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting

N/A

400

Vanquish System

Francis Medical Inc.

Prostate Cancer

04/27

04/29

Wright, Katie

VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated

105

VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga

Veru Inc.

Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer

05/23

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated

1b/2

VERU-100

Veru Inc.

Advanced Prostate Adenocarcinoma

01/23

VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting

N/A

400

Vanquish System

Francis Medical Inc.

Prostate Cancer

04/27

04/29

Gershman, Boris

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting

1/2

STM-416

SURGE Therapeutics

Non-muscle-invasive Bladder Cancer

12/25

Wlajnitz, Tina

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

Thai, Siline

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Hafron, Jason

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting

325

Cretostimogene Grenadenorepvec, CG0070

CG Oncology, Inc.

High-Risk Non-Muscle-Invasive Bladder Cancer

03/27

12/27

NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting

N/A

650

ADXBLADDER

Arquer Diagnostics Ltd

Bladder Cancer

01/23

04/23

Preston, Mark

NCT03216525: Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Recruiting

136

Alvimopan, Entereg, Placebo

Brigham and Women's Hospital, Merck Sharp & Dohme LLC

Bladder Cancer

12/23

06/24

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

350

Europe, Canada, US, RoW

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/26

11/28

Rendon, Ricardo

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting

1100

Europe, Canada, US, RoW

Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy

Prostate Cancer

01/28

07/28

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting

125

Canada, US

Ruvidar® (TLD-1433) Bladder infusion and PDT

Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

06/25

12/25

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

350

Europe, Canada, US, RoW

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/26

11/28

Kates, Max

NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting

112

Europe, US

ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)

Fidia Farmaceutici s.p.a.

Bladder Carcinoma in Situ (CIS)

11/25

11/27

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting

Europe, US

UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine

UroGen Pharma Ltd.

Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent

12/25

BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting

N/A

4400

Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system

Photocure, Catalyst Pharmaceutical Research

Bladder Cancer

12/28

Dickstein, Rian

BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting

190

Japan, US, RoW

Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer

12/27

12/29

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

350

Europe, Canada, US, RoW

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/26

11/28

PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting

ZH9

Prokarium Ltd

NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer

06/25

07/27

CREDIBLE, NCT06394869: Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Recruiting

N/A

1000

Cxbladder Triage Plus

Pacific Edge Limited

Hematuria - Cause Not Known

01/27

03/27

uTRACT, NCT05874921: Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Recruiting

N/A

400

Jelmyto (mitomycin) for pyelocalyceal solution, Jelmyto, UGN-101

UroGen Pharma Ltd.

04/26

01/28

Mazzarella, Brian

ARID II, NCT06873581: Pivotal Study of Voro Urologic Scaffold

Recruiting

266

Voro Urologic Scaffold

Levee Medical, Inc.

Radical Prostatectomy, Stress Urinary Incontinence (SUI)

02/27

02/28

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting

325

Cretostimogene Grenadenorepvec, CG0070

CG Oncology, Inc.

High-Risk Non-Muscle-Invasive Bladder Cancer

03/27

12/27

BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting

N/A

279

Zenflow Spring System, Sham Procedure, Foley Catheter

Zenflow, Inc.

BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)

06/24

06/26

NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Terminated

N/A

NanoTherm Ablation

MagForce USA

Prostate Cancer

07/23

NCT05186740: ProVee Urethral Expander System IDE Study (ProVIDE)

Active, not recruiting

N/A

221

Europe, Canada, US

ProVee Urethral Expander System, ProVee Expander, ProVee, Urethral Access Sheath

ProVerum Medical

Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms

03/24

12/28

NCT06236802: ProVIDE II Bridging Study

Active, not recruiting

N/A

Europe, US

ProVee device, ProVee Expander, ProVee

ProVerum Medical

BPH With Symptomatic Lower Urinary Tract Symptoms

09/24

06/29

NCT06496256: Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

Recruiting

N/A

US, RoW

Barrigel, Transrectal Ultrasound

Palette Life Sciences, Inc., Teleflex

Prostate Cancer

12/27

CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm

Active, not recruiting

N/A

120

Europe, US

UroLift, Rezum

NeoTract, Inc.

Benign Prostatic Hyperplasia

05/25

12/25

WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting

N/A

280

Europe, Canada, US, RoW

Aquablation Therapy, Radical Prostatectomy

PROCEPT BioRobotics

Localized Prostate Cancer

07/27

01/37

VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting

N/A

400

Vanquish System

Francis Medical Inc.

Prostate Cancer

04/27

04/29

Santoyo, Jose

NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting

1/2

STM-416

SURGE Therapeutics

Non-muscle-invasive Bladder Cancer

12/25

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

350

Europe, Canada, US, RoW

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/26

11/28

Penshorn, Jennifer

NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Terminated

N/A

NanoTherm Ablation

MagForce USA

Prostate Cancer

07/23

NCT06496256: Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

Recruiting

N/A

US, RoW

Barrigel, Transrectal Ultrasound

Palette Life Sciences, Inc., Teleflex

Prostate Cancer

12/27

NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Recruiting

N/A

125

US, RoW

Robotic Waterjet Treatment, Aquablation therapy

PROCEPT BioRobotics

Benign Prostatic Hyperplasia, Localized Prostate Cancer

08/25

05/26

VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting

N/A

400

Vanquish System

Francis Medical Inc.

Prostate Cancer

04/27

04/29

Wright, Katie

VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated

105

VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga

Veru Inc.

Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer

05/23

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated

1b/2

VERU-100

Veru Inc.

Advanced Prostate Adenocarcinoma

01/23

VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting

N/A

400

Vanquish System

Francis Medical Inc.

Prostate Cancer

04/27

04/29

Gershman, Boris

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting

1/2

STM-416

SURGE Therapeutics

Non-muscle-invasive Bladder Cancer

12/25

Wlajnitz, Tina

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

Thai, Siline

PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting

364

Canada, US

Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

01/28

01/30

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites